Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution

Author:

Gonçalves Débora Silva1ORCID,Santos Arn Migowski Rocha dos1ORCID,Costa Susanne Crocamo Ventilari da2ORCID,Costa Rodrigo Saar da2ORCID,Senna Katia Marie Simões e1ORCID,Zimmermann Ivan Ricardo3ORCID

Affiliation:

1. Instituto Nacional de Cardiologia, Brazil

2. Instituto Nacional do Câncer José Alencar Gomes da Silva, Brazil

3. Universidade de Brasília, Brazil

Abstract

ABSTRACT Objective: To characterize associated factors and overall survival of women with metastatic breast cancer treated with trastuzumab after its incorporation into the SUS, and additionally to present the direct costs of this technology. Methods: This is a retrospective cohort, based on data from computerized medical records from one of the units of the National Cancer Institute (INCA), in Rio de Janeiro-RJ, Brazil. Women with HER-2 positive metastatic breast cancer undergoing trastuzumab treatment from September 2017 to August 2018 were included. Overall survival was estimated using the Kaplan-Meier method and compared between groups using the log-rank test. Results: 136 women were selected, whose median age at diagnosis was 51 years (range: 21–81 years). The median OS was 43.63 months (95%CI 33.92–53.34). It is observed that the median OS for the population already diagnosed with metastatic disease (stage IV) was significantly lower than for patients diagnosed in stages I-III (37.43 months vs. 48.6 months, p<0, 01). Women without previous use of trastuzumab had a higher median OS than patients pretreated with trastuzumab (45.16 months vs. 40.73 months, p<0.01). Conclusion: Trastuzumab improves survival in HER-2 positive metastatic breast cancer. Brain and multiple metastases are associated with a worse prognosis. It is essential to avoid advanced staging and perform surgical treatment, with emphasis on radical mastectomy. The SUS must adopt policies and strategies for early diagnosis and guarantee access to trastuzumab, considering its high cost.

Publisher

FapUNIFESP (SciELO)

Subject

Epidemiology,Public Health, Environmental and Occupational Health,General Medicine

Reference38 articles.

1. Estimativa 2020: incidência de câncer no Brasil [Internet],2019

2. unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture;Fojo T;JAMA Otolaryngol Neck Surg,2014

3. Comissão Nacional de Incorporação de Tecnologias no SUS. Relatório de recomendação. Diretrizes diagnósticas e terapêuticas do carcinoma de mama [Internet],2018

4. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study;Xiao W;Cancer Manag Res,2018

5. Técnicas de análise de sobrevida;Bustamante-Teixeira MT;Cad Saúde Pública,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3